Cosette Pharmaceuticals Inc., a New Jersey-based pharmaceutical company, announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).
Massive layoffs could be headed to Biogen due to the disappointing rollout of the company’s Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.
Biogen Inc.’s Alzheimer’s drug will be of little help to the company’s third-quarter sales, Wall Street analysts said, as the drugmaker faces an uphill task of convincing hospitals and clinics to use the $56,000-a-year treatment and insurers to reimburse Aduhelm.
Med Ad News talked to the management team of LevLane about the process of building best brands, key factors in producing a successful brand launch, navigating the launch of new products and campaigns with clients during the COVID-19 pandemic, and other topics.
Alkermes Plc said on June 1 the U.S. Food and Drug Administration approved the company’s Lybalvi for the treatment of schizophrenia and bipolar I disorder.
The U.S. Food and Drug Administration approved Heron Therapeutics Inc.’s Zynrelef (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.
One small pharma company is meeting the challenge of COVID-19 by finding new ways to support the practices of its specialist physician customers.
Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
One day after Bristol Myers Squibb announced the commercial launch of the multiple sclerosis drug Zeposia (ozanimod), the company said the medication demonstrated statistically significant efficacy as a potential induction and maintenance therapy for ulcerative colitis.
COVID-19 has changed nearly every aspect of healthcare as we know it. Pharmaceutical commercial organizations must quickly adapt to the present while simultaneously planning for a dramatically different future.
